Blue-Button Regional Trial Screening
Launched by AMERICAN CANCER SOCIETY CANCER ACTION NETWORK · May 31, 2023
Trial Information
Current as of August 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The conduct of cancer clinical trials represents a key final step in testing and proving the efficacy of new treatments relies on successfully conducting clinical trials. However, one in five cancer clinical trials fail due to insufficient patient enrollment, and only about 6% of adult cancer patients are enrolled onto clinical trials, despite the fact that the majority of Americans view clinical trial participation favorably.
The large gap between the willingness of patients to participate in trials and actual trial participate rates suggests the prevalence of many barriers to participati...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult cancer patients attending clinic visit at which they would be screened for clinical trial participation
- Exclusion Criteria:
- • under age 18 years
About American Cancer Society Cancer Action Network
The American Cancer Society Cancer Action Network (ACS CAN) is a leading advocacy organization dedicated to eliminating cancer as a major health problem. As the nonprofit, nonpartisan affiliate of the American Cancer Society, ACS CAN mobilizes grassroots efforts to influence public policy, funding, and research initiatives aimed at cancer prevention, treatment, and survivorship. Through its comprehensive approach, the organization engages with lawmakers, educates the public, and fosters collaborations to enhance cancer-related health outcomes. Their commitment to advancing cancer research and improving access to care underscores their pivotal role in shaping a future where cancer is no longer a threat to public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampa, Florida, United States
Morgantown, West Virginia, United States
Dallas, Texas, United States
Patients applied
Trial Officials
Mark Fleury, PhD
Principal Investigator
ACS CAN
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported